On June 3, 2026 (Beijing time), longevity biotech startup NewLimit announced the completion of a $435 million Series C funding round. The round was led by Peter Thiel's Founders Fund, with continued participation from Abstract Ventures, Kleiner Perkins, NFDG, Eli Lilly Ventures, and Valor Equity Partners, as well as new investors including Thrive Capital, Greenoaks, and Quiet Capital. According to the Wall Street Journal, NewLimit's valuation reached $3.1 billion, more than triple its valuation from a year ago.
In the funding announcement, NewLimit revealed that following breakthrough research results, it is now advancing longevity medicine to human clinical trials. The company's first drug candidate, targeting alcohol-related liver disease, is expected to begin clinical trials next year. "By reprogramming cell age, humans can achieve longer healthspans, and we are now closer than ever to the goal of delaying—or even reversing—aging," the company emphasized.
NewLimit was co-founded by a familiar name in the crypto world: Brian Armstrong, founder and CEO of Coinbase. In 2021, Armstrong, together with former GV partner and bioengineer Blake Byers and stem cell biologist Jacob Kimmel, invested $110 million to launch the company in South San Francisco. Prior to this Series C, NewLimit had completed three earlier funding rounds to advance its cell reprogramming drug development.
NewLimit's scientific foundation rests on the Nobel Prize-winning discovery by Japanese scientist Shinya Yamanaka in 2006. Yamanaka found that activating just a few specific transcription factors could reprogram adult cells back into a youthful, embryonic stem cell-like state—now known as the "Yamanaka Factors." NewLimit's official website explains: "Our drugs work by activating specific transcription factor genes to reprogram the epigenome of cells to a younger state. We already know that this reversal is possible, but for different cell types, the exact combination of transcription factors needed to restore youthful function remains unknown. Discovering these effective gene combinations (payloads) is the core challenge of our work."
In its clinical strategy, NewLimit is taking a disease-specific approach, aiming to secure drug approval for alcohol-related liver disease first before exploring broader applications. Jacob Kimmel, co-founder and CEO, explained that liver disease can be seen as a form of "accelerated aging," presenting the same aging process that everyone undergoes but in a faster and more intense manner.
NewLimit is not the only company targeting radical life extension. In 2022, Sam Altman invested $180 million into Retro Biosciences, which is developing therapies to rejuvenate aging cells and recently disclosed a $1.8 billion valuation. Meanwhile, Altos Labs, reportedly backed by Jeff Bezos, launched in 2022 with $3 billion in funding and has since nearly doubled that amount. Peter Thiel has openly expressed his aversion to death, once stating, "Death is the greatest enemy, but we treat it as a natural law."
From Peter Thiel to Sam Altman to Jeff Bezos, the ultra-wealthy at the pinnacle of technology and finance are pouring billions into anti-aging research. When wealth and power reach their peak, time becomes the only adversary—and the one luxury that money alone cannot buy.
